## Glenda M Macqueen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8785632/publications.pdf

Version: 2024-02-01

128 papers 10,892 citations

45 h-index 100 g-index

128 all docs

128 docs citations

times ranked

128

11106 citing authors

#	Article	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments ( <scp>CANMAT</scp> ) and International Society for Bipolar Disorders ( <scp>ISBD</scp> ) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	1.9	746
3	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
4	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
5	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11, 225-255.	1.9	545
6	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 561-575.	1.9	415
7	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 524-539.	1.9	340
8	Neonatal Outcomes in Women With Untreated Antenatal Depression Compared With Women Without Depression. JAMA Psychiatry, 2016, 73, 826.	11.0	326
9	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 2005, 7, 5-69.	1.9	321
10	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	13.7	306
11	A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2001, 103, 163-170.	4.5	286
12	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 576-587.	1.9	227
13	Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder. Biological Psychiatry, 2008, 64, 880-883.	1.3	224
14	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 510-523.	1.9	209
15	Double-Blind Comparison of Addition of a Second Mood Stabilizer Versus an Antidepressant to an Initial Mood Stabilizer for Treatment of Patients With Bipolar Depression. American Journal of Psychiatry, 2000, 157, 124-126.	7.2	207
16	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders, 2006, 8, 721-739.	1.9	202
17	Adolescence as a unique developmental period. Journal of Psychiatry and Neuroscience, 2015, 40, 291-293.	2.4	179
18	Systematic review of the neural basis of social cognition in patients with mood disorders. Journal of Psychiatry and Neuroscience, 2012, 37, 154-169.	2.4	172

#	Article	IF	CITATIONS
19	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 588-603.	1.9	165
20	Pregnancy-related anxiety: A concept analysis. International Journal of Nursing Studies, 2016, 55, 115-130.	5.6	150
21	Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. Molecular Psychiatry, 2021, 26, 5124-5139.	7.9	136
22	Associations Between Bipolar Disorder and Metabolic Syndrome. Journal of Clinical Psychiatry, 2006, 67, 1034-1041.	2.2	135
23	Cognitive dysfunction in major depression and bipolar disorder: <scp>A</scp> ssessment and treatment options. Psychiatry and Clinical Neurosciences, 2017, 71, 18-27.	1.8	131
24	Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2000, 101, 374-381.	4.5	130
25	Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. Journal of Affective Disorders, 2018, 233, 21-35.	4.1	124
26	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 2016, 16, 105.	2.6	114
27	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 287-302.	4.8	113
28	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 803-810.	2.2	111
29	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). Journal of the Canadian Association of Gastroenterology, 2019, 2, 6-29.	0.3	104
30	A review of fMRI studies during visual emotive processing in major depressive disorder. World Journal of Biological Psychiatry, 2015, 16, 448-471.	2.6	102
31	Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. Canadian Journal of Psychiatry, 2017, 62, 11-23.	1.9	90
32	A randomized, doubleâ€blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disorders, 2012, 14, 697-706.	1.9	81
33	Thalamocortical connectivity in major depressive disorder. Journal of Affective Disorders, 2017, 217, 125-131.	4.1	70
34	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology, 2018, 21, 128-144.	2.1	68
35	Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. Journal of Psychiatry and Neuroscience, 2009, 34, 343-9.	2.4	64
36	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	61

#	Article	IF	CITATIONS
37	Changes in cortical thickness across the lifespan in major depressive disorder. Psychiatry Research - Neuroimaging, 2013, 214, 204-211.	1.8	59
38	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 506-509.	1.9	58
39	Altered self-report of empathic responding in patients with bipolar disorder. Psychiatry Research, 2010, 178, 354-358.	3.3	56
40	Neural correlates of cognitive remediation in patients with mood disorders. Psychiatry Research - Neuroimaging, 2013, 214, 142-152.	1.8	55
41	Subgenual anterior cingulate cortex and hippocampal volumes in depressed youth: The role of comorbidity and age. Journal of Affective Disorders, 2016, 190, 726-732.	4.1	55
42	Alterations in empathic responding among women with posttraumatic stress disorder associated with childhood trauma. Brain and Behavior, 2014, 4, 381-389.	2.2	52
43	A twoâ€illness model of bipolar disorder 1. Bipolar Disorders, 1999, 1, 25-30.	1.9	51
44	Functional Recovery in Major Depressive Disorder. primary care companion for CNS disorders, The, 2016, 18, .	0.6	51
45	Theory of mind deficits in patients with mild symptoms of major depressive disorder. Psychiatry Research, 2013, 210, 672-674.	3.3	49
46	A review of factors that moderate autobiographical memory performance in patients with major depressive disorder. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 1122-1144.	1.3	48
47	An Update on Antidepressant Use in Bipolar Depression. Current Psychiatry Reports, 2012, 14, 696-704.	4.5	47
48	Mental Health Services for Students at Postsecondary Institutions: A National Survey. Canadian Journal of Psychiatry, 2016, 61, 766-775.	1.9	47
49	Patients with bipolar disorder show impaired performance on complex tests of social cognition. Psychiatry Research, 2012, 200, 258-264.	3.3	44
50	Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study. British Journal of Psychiatry, 2017, 210, 54-60.	2.8	44
51	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. Journal of Affective Disorders, 2014, 167, 104-111.	4.1	43
52	A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. Journal of Affective Disorders, 2017, 210, 57-65.	4.1	42
53	Clinical staging for youth atâ€risk for serious mental illness. Microbial Biotechnology, 2019, 13, 1416-1423.	1.7	42
54	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39

#	Article	IF	CITATIONS
55	Impaired theory of mind performance in patients with recurrent bipolar disorder: Moderating effect of cognitive load. Psychiatry Research, 2010, 177, 261-262.	3.3	38
56	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology, 2020, 45, 283-291.	5.4	37
57	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	2.4	37
58	Pregnant Women's Views on the Feasibility and Acceptability of Web-Based Mental Health E-Screening Versus Paper-Based Screening: A Randomized Controlled Trial. Journal of Medical Internet Research, 2017, 19, e88.	4.3	35
59	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. Frontiers in Psychiatry, 2021, 12, 617997.	2.6	32
60	Cortical thickness and emotion processing in young adults with mild to moderate depression: a preliminary study. BMC Psychiatry, 2016, 16, 38.	2.6	29
61	Youth at-risk for serious mental illness: methods of the PROCAN study. BMC Psychiatry, 2018, 18, 219.	2.6	29
62	Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay. International Journal of Bipolar Disorders, 2014, 2, 1.	2.2	28
63	The gut microbiota and psychiatric illness. Journal of Psychiatry and Neuroscience, 2017, 42, 75-77.	2.4	28
64	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	2.6	28
65	Association between solar insolation and a history of suicide attempts in bipolar I disorder. Journal of Psychiatric Research, 2019, 113, 1-9.	3.1	25
66	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Annals of Clinical Psychiatry, 2012, 24, 56-68.	0.6	25
67	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. Neurolmage, 2019, 197, 589-597.	4.2	24
68	Yoga as a Therapy for Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2020, 65, 2503-2514.	2.3	24
69	A Survey of Mental Health Services at Post-Secondary Institutions in Alberta. Canadian Journal of Psychiatry, 2014, 59, 250-258.	1.9	23
70	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	5.4	23
71	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	4.5	22
72	Childhood trauma and amygdala nuclei volumes in youth at risk for mental illness. Psychological Medicine, 2022, 52, 1192-1199.	4.5	22

#	Article	IF	Citations
73	Galantamine as an Adjunctive Treatment in Major Depression. Journal of Clinical Psychopharmacology, 2008, 28, 357-359.	1.4	21
74	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 913-924.	1.5	21
75	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. Journal of Affective Disorders, 2019, 257, 765-773.	4.1	20
76	Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disorders, 2015, 17, 86-96.	1.9	19
77	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
78	Neurocognitive deficits in a transdiagnostic clinical staging model. Psychiatry Research, 2018, 270, 1137-1142.	3.3	17
79	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2020, 50, 2536-2547.	4.5	17
80	Family functioning in youth at-risk for serious mental illness. Comprehensive Psychiatry, 2018, 87, 17-24.	3.1	16
81	Psychological factors that may confer risk for bipolar disorder. Cognitive Neuropsychiatry, 2013, 18, 115-128.	1.3	15
82	Sleep disturbances in youth atâ€risk for serious mental illness. Microbial Biotechnology, 2020, 14, 373-378.	1.7	14
83	Aberrant limbic brain structures in young individuals at risk for mental illness. Psychiatry and Clinical Neurosciences, 2020, 74, 294-302.	1.8	14
84	Comparing the feasibility, acceptability, clinical-, and cost-effectiveness of mental health e-screening to paper-based screening on the detection of depression, anxiety, and psychosocial risk in pregnant women: a study protocol of a randomized, parallel-group, superiority trial. Trials, 2014, 15, 3.	1.6	13
85	Intrinsic thalamocortical connectivity varies in the age of onset subtypes in major depressive disorder. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 75-82.	2.2	13
86	Aerobic exercise in depressed youth: A feasibility and clinical outcomes pilot. Microbial Biotechnology, 2019, 13, 128-132.	1.7	13
87	Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5â€HTTLPRâ€S/Lg polymorphisms. Human Psychopharmacology, 2016, 31, 144-155.	1.5	12
88	Pregnant Women's Perceptions of the Risks and Benefits of Disclosure During Web-Based Mental Health E-Screening Versus Paper-Based Screening: Randomized Controlled Trial. JMIR Mental Health, 2017, 4, e42.	3.3	12
89	Psychosocial Interventions for Bipolar Disorder and Coping Style Modification: Similar Clinical Outcomes, Similar Mechanisms?. Canadian Journal of Psychiatry, 2013, 58, 482-486.	1.9	11
90	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194.	4.8	11

#	Article	IF	Citations
91	The impact of personality disorders on treatment outcome in bipolar disorder: A review. Personality and Mental Health, 2007, $1$ , $2$ - $13$ .	1.2	10
92	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. NeuroImage: Clinical, 2020, 25, 102178.	2.7	10
93	Assessing personal financial management in patients with bipolar disorder and its relation to impulsivity and response inhibition. Cognitive Neuropsychiatry, 2015, 20, 424-437.	1.3	9
94	Treatment History of Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2019, 64, 145-154.	1.9	8
95	A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry, 2019, 19, 285.	2.6	8
96	Social and role functioning in youth at risk of serious mental illness. Microbial Biotechnology, 2020, 14, 463-469.	1.7	8
97	Exploring brain connectivity changes in major depressive disorder using <scp>functionalâ€structural</scp> data fusion: A CANâ€BINDâ€1 study. Human Brain Mapping, 2021, 42, 4940-4957.	3.6	8
98	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	2.7	8
99	Patient Engagement and Multidisciplinary Involvement Has an Impact on Clinical Guideline Development and Decisions: A Comparison of Two Irritable Bowel Syndrome Guidelines Using the Same Data. Journal of the Canadian Association of Gastroenterology, 2019, 2, 30-36.	0.3	7
100	Trauma in Youth At-Risk for Serious Mental Illness. Journal of Nervous and Mental Disease, 2020, 208, 70-76.	1.0	7
101	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. Human Brain Mapping, 2020, 41, 1400-1415.	3.6	7
102	The accuracy of depression risk perception in high risk Canadians. Journal of Affective Disorders, 2020, 265, 410-415.	4.1	7
103	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. Journal of Affective Disorders, 2020, 264, 414-424.	4.1	6
104	Clinical staging for youth atâ€risk for serious mental illness: A longitudinal perspective. Microbial Biotechnology, 2021, 15, 1188-1196.	1.7	6
105	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16ÂWeeks of Pharmacotherapy: A CAN-BIND Report. Cerebral Cortex, 2022, 32, 1223-1243.	2.9	6
106	Cerebello-limbic functional connectivity patterns in youth at clinical high risk for psychosis. Schizophrenia Research, 2022, 240, 220-227.	2.0	6
107	Pilot aerobic exercise intervention for youth atâ€risk for serious mental illness. Microbial Biotechnology, 2021, 15, 547-553.	1.7	5
108	Personality and risk for serious mental illness. Microbial Biotechnology, 2021, 15, 133-139.	1.7	5

#	Article	IF	Citations
109	Recruitment Challenges for Studies of Deep Brain Stimulation for Treatment-Resistant Depression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 765-775.	2.2	5
110	Resting state fMRI scanner instabilities revealed by longitudinal phantom scans in a multi-center study. NeuroImage, 2021, 237, 118197.	4.2	5
111	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	1.9	5
112	A novel task for examining the neural basis of Theory of Mind deficits in bipolar disorder. Psychiatry Research - Neuroimaging, 2018, 282, 143-150.	1.8	4
113	White Matter Connectivity in Youth at Risk for Serious Mental Illness: A Longitudinal Analysis. Psychiatry Research - Neuroimaging, 2020, 302, 111106.	1.8	4
114	The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. BMC Public Health, 2020, 20, 876.	2.9	4
115	Altered hippocampal function with preserved cognitive performance in treatment-naive major depressive disorder. NeuroReport, 2019, 30, 46-52.	1.2	3
116	Functional imaging in youth at risk for transdiagnostic serious mental illness: Initial results from the PROCAN study. Microbial Biotechnology, 2020, 15, 1276-1291.	1.7	3
117	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. Frontiers in Neuroinformatics, 2021, 15, 622951.	2.5	2
118	Reply: â€~Lithium and Increased Hippocampal Volume: More Tissue or More Water?. Neuropsychopharmacology, 2008, 33, 1775-1775.	5.4	1
119	Predicting Hospital Length of Stay for Geriatric Patients with Mood Disorders. Canadian Journal of Psychiatry, 2012, 57, 627-634.	1.9	1
120	Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression. Journal of Visualized Experiments, 2015, , e52061.	0.3	1
121	Substance use in youth atâ€risk for serious mental illness. Microbial Biotechnology, 2021, 15, 634-641.	1.7	1
122	Longitudinal Trends in Medication Treatment for Youth At-Risk for Serious Mental Illness. Canadian Journal of Psychiatry, 2021, 66, 418-420.	1.9	1
123	Neuroimaging and electrophysiology in predicting treatment responsiveness in depression: bridging the lab-to-clinic divide?. Canadian Journal of Psychiatry, 2013, 58, 497-8.	1.9	1
124	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. Canadian Journal of Psychiatry, 2017, 62, 77-78.	1.9	0
125	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. Canadian Journal of Psychiatry, 2017, 62, 353-354.	1.9	0
126	Aerobic exercise and hippocampal change in youth at risk of serious mental illness. Psychiatry Research - Neuroimaging, 2020, 305, 111199.	1.8	0

#	Article	IF	CITATIONS
127	Cognition and its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1. Canadian	1.9	0
128	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. Cerebellum, 2023, 22, 26-36.	2.5	0